Pfizer PFE Stock
Pfizer Price Chart
Pfizer PFE Financial and Trading Overview
| Pfizer stock price | 30.03 USD |
| Previous Close | 30.42 USD |
| Open | 30.28 USD |
| Bid | 29.97 USD x 390000 |
| Ask | 30.04 USD x 570000 |
| Day's Range | 29.81 - 30.32 USD |
| 52 Week Range | 23.62 - 30.44 USD |
| Volume | 29.4M USD |
| Avg. Volume | 34.54M USD |
| Market Cap | 171.16B USD |
| Beta (5Y Monthly) | 0.276 |
| PE Ratio (TTM) | 39 |
| EPS (TTM) | 0.77 USD |
| Forward Dividend & Yield | 1.72 (5.72%) |
| Ex-Dividend Date | November 6, 2026 |
| 1y Target Est | 29.26 USD |
PFE Valuation Measures
| Enterprise Value | 223.24B USD |
| Trailing P/E | 39 |
| Forward P/E | 10.412297 |
| PEG Ratio (5 yr expected) | 13.76 |
| Price/Sales (ttm) | 2.6871579 |
| Price/Book (mrq) | 2.0089645 |
| Enterprise Value/Revenue | 3.505 |
| Enterprise Value/EBITDA | 8.795 |
Trading Information
Pfizer Stock Price History
| Beta (5Y Monthly) | 0.276 |
| 52-Week Change | 21.23% |
| S&P500 52-Week Change | 10.88% |
| 52 Week High | 30.44 USD |
| 52 Week Low | 23.62 USD |
| 50-Day Moving Average | 28.3 USD |
| 200-Day Moving Average | 26.68 USD |
PFE Share Statistics
| Avg. Volume (3 month) | 34.54M USD |
| Avg. Daily Volume (10-Days) | 28.19M USD |
| Shares Outstanding | 5.7B |
| Float | 5.69B |
| Short Ratio | 4.48 |
| % Held by Insiders | 0.10% |
| % Held by Institutions | 69.05% |
| Shares Short | 150.22M |
| Short % of Float | 2.64% |
| Short % of Shares Outstanding | 2.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.72 |
| Trailing Annual Dividend Yield | 5.65% |
| 5 Year Average Dividend Yield | 478.00% |
| Payout Ratio | 2.2632 |
| Last Split Factor | 1054:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 28, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 6.80% |
| Operating Margin (ttm) | 27.87% |
| Gross Margin | 74.71% |
| EBITDA Margin | 39.85% |
Management Effectiveness
| Return on Assets (ttm) | 5.78% |
| Return on Equity (ttm) | 5.01% |
Income Statement
| Revenue (ttm) | 63.7B USD |
| Revenue Per Share (ttm) | 11.19 USD |
| Quarterly Revenue Growth (yoy) | 2.60% |
| Gross Profit (ttm) | 47.59B USD |
| EBITDA | 25.38B USD |
| Net Income Avi to Common (ttm) | 4.34B USD |
| Diluted EPS (ttm) | 0.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.7B USD |
| Total Cash Per Share (mrq) | 2.05 USD |
| Total Debt (mrq) | 63.48B USD |
| Total Debt/Equity (mrq) | 74.25 USD |
| Current Ratio (mrq) | 1.267 |
| Book Value Per Share (mrq) | 14.948 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 13.4B USD |
| Levered Free Cash Flow (ttm) | 12.49B USD |
Profile of Pfizer
| Country | United States |
| State | NY |
| City | New York |
| Address | 66 Hudson Boulevard East |
| ZIP | 10001-2192 |
| Phone | 212 733 2323 |
| Website | https://www.pfizer.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 75000 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Q&A For Pfizer Stock
What is a current PFE stock price?
Pfizer PFE stock price today per share is 30.03 USD.
How to purchase Pfizer stock?
You can buy PFE shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pfizer?
The stock symbol or ticker of Pfizer is PFE.
Which industry does the Pfizer company belong to?
The Pfizer industry is Drug Manufacturers - General.
How many shares does Pfizer have in circulation?
The max supply of Pfizer shares is 5.7B.
What is Pfizer Price to Earnings Ratio (PE Ratio)?
Pfizer PE Ratio is 39.00000000 now.
What was Pfizer earnings per share over the trailing 12 months (TTM)?
Pfizer EPS is 0.77 USD over the trailing 12 months.
Which sector does the Pfizer company belong to?
The Pfizer sector is Healthcare.
Pfizer PFE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
S&P 500 INDEX
SPX
US
|
7623.68 USD — |
-0.52
|
2.77B USD — | — — | — — | — - | 2.77B USD — |
S&P 500 (Yahoo.com)
GSPC
US
|
7623.68 USD — |
-0.52
|
2.75B USD — | 7612.07 USD — | 7660.15 USD — | — - | 2.75B USD — |
S&P 100
SP100
US
|
3777.59 USD — |
-0.49
|
1.15B USD — | 3773.3 USD — | 3797.23 USD — | — - | 1.15B USD — |
Dow Jones Composite Average
DJA
US
|
16366.42 USD — |
-1.17
|
483.5M USD — | 16282.86 USD — | 16511.4 USD — | — - | 483.5M USD — |
US Tech US Low Volatility Divide
LVDA
US
|
1363.68 USD — |
-1.09
|
— — | 1360.49 USD — | 1377.83 USD — | — - | — — |
Dorsey Wright Momentum Plus Div
DWAMY
US
|
1792 USD — |
-0.31
|
— — | 1792 USD — | 1792 USD — | — - | — — |
Better Investing 100
BIXX
US
|
245.36 USD — |
0
|
— — | — — | — — | — - | — — |
NYSE Composite Index
NYA
US
|
24117.27 USD — |
-0.65
|
— — | — — | — — | — - | — — |
US Tech US Price Setters Index
NQPRCE
US
|
3113.99 USD — |
-1.01
|
— — | 3105.63 USD — | 3129.46 USD — | — - | — — |
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
3770.94 USD — |
-0.28
|
— — | 3736.98 USD — | 3784.46 USD — | — - | — — |
US Tech CRD Global Sustainabilit
NQCRD
US
|
1735.62 USD — |
0
|
— — | 1715.94 USD — | 1757.95 USD — | — - | — — |
The Capital Strength Index
NQCAPST
US
|
3685.47 USD — |
-1.39
|
— — | 3672.45 USD — | 3718.46 USD — | — - | — — |
NYSE Arca Pharmaceutical Index
DRG
US
|
1298.72 USD — |
-1.6
|
— — | — — | — — | — - | — — |
US Tech US Broad Dividend Achiev
DAA
US
|
4654.81 USD — |
-0.76
|
— — | 4641.75 USD — | 4673.2 USD — | — - | — — |
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
2264.93 USD — |
-1.19
|
— — | 2251.22 USD — | 2281.71 USD — | — - | — — |
US Tech Factor Family US Low Vol
NQFFUSLV
US
|
1914.57 USD — |
-1.05
|
— — | 1908.8 USD — | 1930.32 USD — | — - | — — |
US Tech DM Ex Japan Large Mid Ca
NQDMXJPLMAUD
US
|
2100.38 AUD 1467.26 USD |
<0.01
|
— — | 2100.38 AUD 1467.26 USD | 2100.38 AUD 1467.26 USD | — - | — — |
The Capital Strength Net Total
NQCAPSTN
US
|
4419.19 USD — |
-1.38
|
— — | 4403.57 USD — | 4458.74 USD — | — - | — — |
- {{ link.label }} {{link}}


